adam10

INCB3619 is a selective and potent inhibitor of ADAM with antitumour effects, inhibiting ADAM10, ADAM17, MMP12 and MMP15.

JG26 is a potent inhibitor of ADAM17, which can inhibit ADAM8, ADAM17, ADAM10 and MMP-12, with IC50 values of 12 nM, 1.9 nM, 150 nM and 9.4 nM, respectively, and can be used to study the immune system of the body.

GI254023X is a MMP9 and ADAM10 inhibitor with IC50 values ​​of 2.5 and 5.3 nM, respectively. GI254023X can also significantly inhibit the proliferation of Jurkat cells and induce apoptosis.

GW280264X (Carbamic acid) is an inhibitor of ADAM17 .

Anti-Human/Mouse/Bovine ADAM10 Antibody (8C7) is a monoclonal inhibitory antibody targeting human, mouse and bovine ADAM10 protein, which can be used in immunological research.

KP-457 is a specific inhibitor of a disintegrin-metalloproteinase 17 (ADAM17) and a TNFα converting enzyme TACE inhibitor that blocks the production of soluble TNF (sTNF).

P2X1 receptor antagonist

TMI-1 (WAY-171318), a novel orally active inhibitor of ADAM17 (TACE) and MMP, induces tumor apoptosis in a breast cancer.

Aderbasib (INCB007839) is an orally active and potent ADAM10 and ADAM17 inhibitor with antitumor activity, used for studying cancer and cardiovascular diseases.

Anti-MICB Antibody is a humanized monoclonal antibody targeting MHC class I polypeptide-related sequence B (MICB). MICB is a critical ligand for the activating receptor NKG2D expressed on NK cells and CD8+ T cells. Tumor cells often evade immune surveillance by proteolytically shedding MICB via proteases (e.g., ADAM10/17), leading to reduced surface ligand density. This antibody typically binds to the α3 domain of MICB, specifically inhibiting its proteolytic shedding and stabilizing MICB expression on the tumor cell surface. This process restores NKG2D-mediated immune recognition and enhances the cytotoxic activity of NK cells and T cells against tumors, serving as a vital tool for researching tumor immune evasion mechanisms and developing novel immunotherapies.

CCKBRagonist-1 (Compound 3r1) is a selective agonist for the cholecystokinin B receptor (CCKBR) that preferentially activates the Gq protein, with an EC50 of 35 pM. It significantly enhances neuronal survival at an EC50 of 37 pM. CCKBRagonist-1 improves cognitive decline in mice by upregulating α-secretase (ADAM10) and the calcium signaling molecule PLCB4, reduces the number of amyloid β (Aβ) plaques, and promotes long-term potentiation (LTP). This compound is useful for Alzheimer's disease research.